130 related articles for article (PubMed ID: 18727465)
1. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.
Moore ML; Quinn JM
Ann Allergy Asthma Immunol; 2008 Aug; 101(2):114-21; quiz 122-3, 178. PubMed ID: 18727465
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous immunoglobulin replacement therapy in patients with immunodeficiencies - impact of drug packaging and administration method on patient reported outcomes.
Mallick R; Solomon G; Bassett P; Zhang X; Patel P; Lepeshkina O
BMC Immunol; 2024 Feb; 25(1):18. PubMed ID: 38378441
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.
Skoda-Smith S; Torgerson TR; Ochs HD
Ther Clin Risk Manag; 2010 Feb; 6():1-10. PubMed ID: 20169031
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic immunoglobulin therapy for pediatric congenital myotonic dystrophy.
Uejima Y; Sato S
Immunol Med; 2024 Jun; 47(2):106-109. PubMed ID: 38270551
[TBL] [Abstract][Full Text] [Related]
5. Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy.
Stubbs A; Bangs C; Shillitoe B; Edgar JD; Burns SO; Thomas M; Alachkar H; Buckland M; McDermott E; Arumugakani G; Jolles S; Herriot R; Arkwright PD
Clin Exp Immunol; 2018 Feb; 191(2):212-219. PubMed ID: 28990652
[TBL] [Abstract][Full Text] [Related]
6. The Experiences of Children with Primary Immunodeficiency Who Receive Immunoglobulin Subcutaneously Instead of Intravenously.
Köse S; Sabetsarvestani R; Geçkil E; Kaleci E; Dönmez H
J Pediatr Health Care; 2024; 38(1):13-20. PubMed ID: 37702646
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin replacement therapies in inborn errors of immunity: a review.
Sil A; Basu S; Joshi V; Pilania RK; Siniah S; Suri D; Rawat A; Singh S
Front Pediatr; 2024; 12():1368755. PubMed ID: 38425666
[TBL] [Abstract][Full Text] [Related]
8. A retrospective review of immunology patients with primary and/or secondary immunodeficiency, demonstrating the benefits of the rapid transitioning from intravenous immunoglobulin to subcutaneous immunoglobulin at the onset of the COVID-19 pandemic.
Boyle T; Zaragoza R; Li J; Cvetanovski V; Weaver P; Hoyle P; Venkatesha V; Fernando SL
Intern Med J; 2023 Jul; 53(7):1256-1260. PubMed ID: 37092797
[TBL] [Abstract][Full Text] [Related]
9. Update on Infections in Primary Antibody Deficiencies.
Demirdag YY; Gupta S
Front Immunol; 2021; 12():634181. PubMed ID: 33643318
[TBL] [Abstract][Full Text] [Related]
10. How I treat common variable immune deficiency.
Cunningham-Rundles C
Blood; 2010 Jul; 116(1):7-15. PubMed ID: 20332369
[TBL] [Abstract][Full Text] [Related]
11. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
[TBL] [Abstract][Full Text] [Related]
12. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.
Jolles S; Chapel H; Litzman J
Clin Exp Immunol; 2017 Jun; 188(3):333-341. PubMed ID: 28000208
[TBL] [Abstract][Full Text] [Related]
13. A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis.
Shabaninejad H; Asgharzadeh A; Rezaei N; Rezapoor A
Expert Rev Clin Immunol; 2016; 12(5):595-602. PubMed ID: 26902306
[TBL] [Abstract][Full Text] [Related]
14. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N
J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.
Gupta S; DeAngelo J; Melamed I; Walter JE; Kobayashi AL; Bridges T; Sublett JW; Bernstein JA; Koterba A; Manning M; Maltese J; Hoeller S; Turpel-Kantor E; Kreuwel H; Kobayashi RH
J Clin Immunol; 2023 Aug; 43(6):1414-1425. PubMed ID: 37160610
[TBL] [Abstract][Full Text] [Related]
17. In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins.
Leidenmühler P; Höfinghoff J; Haider N; Brachtl G; Weiller M; Bilic I; Gangadharan B
Drug Deliv Transl Res; 2023 Sep; 13(9):2367-2377. PubMed ID: 36920736
[TBL] [Abstract][Full Text] [Related]
18. Primary Immunodeficiencies: Diseases of Children and Adults - A Review.
Lewandowicz-Uszyńska A; Pasternak G; Świerkot J; Bogunia-Kubik K
Adv Exp Med Biol; 2021; 1289():37-54. PubMed ID: 32803731
[TBL] [Abstract][Full Text] [Related]
19. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
[TBL] [Abstract][Full Text] [Related]
20. [Common variable immune deficiency lately revealed by gastrointestinal problems: about a case].
Ezzaitouni F; Thiyfa Y; Tahiri M; Haddad F; Hliwa W; Bellabah A; Badre W
Pan Afr Med J; 2017; 28():48. PubMed ID: 29184600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
